Vaxcyte (PCVX) Non-Current Assets (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Non-Current Assets data on file, last reported at $1.5 billion in Q1 2026.

• On a quarterly basis, Non-Current Assets fell 7.63% year-over-year to $1.5 billion in Q1 2026; TTM through Mar 2026 was $1.5 billion, a 7.63% decrease from a year earlier, with the FY2025 full-year figure at $1.4 billion, down 20.19% from the prior year.
• Non-Current Assets for Q1 2026 stood at $1.5 billion, up from $1.4 billion in the prior quarter.
• Over the last five years, Non-Current Assets for PCVX reached as high as $1.7 billion in Q4 2024 and fell as low as $42.3 million in Q3 2022.
• Historically, Non-Current Assets has averaged $758.9 million across 5 years, with a median of $574.2 million in 2024.
• Across the five-year window, Non-Current Assets soared 570.85% in 2024 and declined 20.19% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $63.6 million in 2022, then soared by 390.33% to $312.0 million in 2023, then jumped by 452.42% to $1.7 billion in 2024, then retreated by 20.19% to $1.4 billion in 2025, then increased by 11.59% to $1.5 billion in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $1.5 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.